Skip to main content

Advertisement

Table 2 Efficacy and safety outcomes for treatment of acute VTE: DOACs versus VKA

From: Management of venous thromboembolism: an update

Trial Name [Ref] RE-COVER [15] RE-COVER II [16] EINSTEIN-DVT [17] EINSTEIN-PE [18] AMPLIFY [19] Hokusai-VTE [20]
Primary Efficacy Outcome DOAC vs VKA (%) Recurrent symptomatic VTE or related death: 2.4 vs 2.1a Recurrent symptomatic VTE or related mortality: 2.3 vs 2.2a Recurrent symptomatic VTE: 2.1 vs 3.0a Recurrent symptomatic VTE: 2.1 vs 1.8a Recurrent symptomatic VTE or related mortality: 2.3 vs 2.7a Recurrent symptomatic VTE or related mortality: 3.2 vs 3.5a
Primary Safety Outcome(s) Major bleeding; Major or CRNM bleeding: Any bleeding Major bleeding Major or CRNM bleeding: Any bleeding Major or CRNM bleeding Major or CRNM bleeding Major bleeding Major or CRNM bleeding
Major Bleeding DOAC vs VKA (%) 1.6 vs 1.9 1.2 vs 1.7 0.8 vs 1.2 1.1a vs 2.2 0.6a vs 1.8 1.4 vs 1.6
Major or CRNM Bleeding DOAC vs VKA (%) 5.6 vs 8.8 5.0 vs 7.9 8.1 vs 8.1 10.3 vs 11.4 4.3a vs 9.7 8.5a vs 10.3
  1. DOAC direct oral anticoagulant, CRNM clinically relevant non-major, DOAC direct oral anticoagulants, VKA vitamin K antagonists, VTE venous thromboembolism
  2. aStatistically significant difference between the two groups